Use of the signal peptide platform, which targets infected cThis collaboration agreement is an central milestone in the pre-clinical stage of our COVID-19 vaccine candidate research, and provides a clear pathway to potential clinical trials during 2020, said David Goren, Vaxils Chairman and Chief Executive Officer. He continued to say the The Aviv Medical Center is a leading hospital and is at the forefront of fighting the COVID-19 pandemic in Israel. We look forward to working with Dr. Hagin and their world-class medical and research teams on this program. Dr. Hagin added Use of the signal peptide platform, which targets infected cells rather than the virus is unique and exciting. I see great potential in this innovative approach to develop a potential COVID-19 vaccine. We share Vaxils vision of creating a vaccine quickly for the benefit of people all over the world.